{
    "doi": "https://doi.org/10.1182/blood.V108.11.4968.4968",
    "article_title": "Therapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) for Relapsed or Untreated Progressive Chronic Lymphocytic Leukemia (CLL). A Single Center Experience. ",
    "article_date": "November 16, 2006",
    "session_type": "Abstracts Not Selected for Presentation",
    "abstract_text": "Purpose: To evaluate the efficacy of FCR in improving complete remission (CR), disease-free survival (DFS) and overall survival (OS) rates in patients previously treated with chlorambucil-prednisolone and untreated CLL patients. Patients and methods: A total of 45 CLL patients started FCR. Forty-one patients completed treatment: 16 following previous relapse and 25 previously untreated with progressive disease. Four patients are still receiving treatment. Median patient age was 63 years (range 34\u201388 years). Binet\u2019s stage were: A: 8%, B: 34% and C: 58%. CD38 expression was positive (> 7% of cells) in 56% of patients and negative in 44%. FCR consisted of: fludarabine (25 mg/m 2 /day \u00d7 3); cyclophosphamide (250 mg/m 2 /day \u00d7 3) and rituximab (375 mg/m 2 /day \u00d7 1), all given intravenously, every 4 weeks for 4\u20136 cycles. CR was defined by CLL/NCI-WG criteria. Minimal residual disease (MRD) negativity was < 1% CD19, CD5 positive cells in peripheral blood and bone marrow. Results: The results of this study are detailed in Table 1. To summarise: CR: 69%; nodular partial remission (PR): 15%; PR: 7% and stable disease: 2%. Grade 3\u20134 neutropenia occurred in 33% of patients and 34% required hospitalization due to infections. Table 1: Patient details following FCR treatment  . Patients . % CR . % MRD negative . % DFS 36 mo . P . % OS 36 mo . P . Untreated 25 87 96 90  95  Treated 16 53 87 75 0.10 89 0.90 Total 41 74 92 83  93  CD38 Positive 23 71 90 71 0.02 87 0.27 CD38 Negative 18 76 94 100  100  . Patients . % CR . % MRD negative . % DFS 36 mo . P . % OS 36 mo . P . Untreated 25 87 96 90  95  Treated 16 53 87 75 0.10 89 0.90 Total 41 74 92 83  93  CD38 Positive 23 71 90 71 0.02 87 0.27 CD38 Negative 18 76 94 100  100  View Large Conclusions: FCR induces a high CR (74%) and DFS (83%) rate and increases MRD negativity (92%). Significantly higher DFS rates at 36 months were observed in patients who were CD38 negative vs. CD38 positive (100 % vs. 71% P=0.02).",
    "topics": [
        "chronic b-cell leukemias",
        "chronic lymphocytic leukemia",
        "cyclophosphamide",
        "fludarabine",
        "rituximab",
        "cd19 antigens",
        "chlorambucil",
        "complete remission",
        "infections",
        "neoplasm, residual"
    ],
    "author_names": [
        "Carolina Pavlovsky, MD",
        "Santiago Pavlovsky, MD PhD",
        "Maria L. Pardo, MD",
        "Sandra Sapia, MD",
        "Mariela Monreal, MD",
        "Claudia Corrado, MDd",
        "Miguel A. Pavlovsky, MD",
        "Isolda Fernandez, MD",
        "Mariana Juni, MS"
    ],
    "author_dict_list": [
        {
            "author_name": "Carolina Pavlovsky, MD",
            "author_affiliations": [
                "Oncohematology, Fundaleu, Buenos Aires, Argentina"
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Santiago Pavlovsky, MD PhD",
            "author_affiliations": [
                "Oncohematology, Fundaleu, Buenos Aires, Argentina"
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Maria L. Pardo, MD",
            "author_affiliations": [
                "Oncohematology, Fundaleu, Buenos Aires, Argentina"
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Sandra Sapia, MD",
            "author_affiliations": [
                "Oncohematology, Fundaleu, Buenos Aires, Argentina"
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Mariela Monreal, MD",
            "author_affiliations": [
                "Oncohematology, Fundaleu, Buenos Aires, Argentina"
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Claudia Corrado, MDd",
            "author_affiliations": [
                "Oncohematology, Fundaleu, Buenos Aires, Argentina"
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Miguel A. Pavlovsky, MD",
            "author_affiliations": [
                "Oncohematology, Fundaleu, Buenos Aires, Argentina"
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Isolda Fernandez, MD",
            "author_affiliations": [
                "Oncohematology, Fundaleu, Buenos Aires, Argentina"
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Mariana Juni, MS",
            "author_affiliations": [
                "Oncohematology, Fundaleu, Buenos Aires, Argentina"
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-05-01T06:35:35",
    "is_scraped": "1"
}